IPO: Emcure Pharmaceuticals

Emcure Pharmaceuticals, a generic drug maker, is launching its IPO (initial public offering) on July 3, 2024. Below's a breakdown of the company's strengths, weaknesses, and growth prospects to help investors make an informed decision.

In a nutshell

• Quality : The company's three-year average ROE and ROCE was nearly 24 per cent each between FY22 and FY24.
  
• Growth : The company's revenue grew 6.6 per cent per annum during FY22-FY24 but its profit after tax contracted 13.3 per cent per annum during this period.
  
• Valuation : Post the IPO, the stock will be valued at a P/E and P/B ratio of 36.1 and 5.1 times, respectively.
  
• Overview: Growing expenditure and penetration in the Indian healthcare sector, along with the 'China plus one' strategy will benefit Emcure Pharma in coming years. However, being a generic drug company, it operates in a highly competitive business environment that may hinder its profitability.

About Emcure Pharma

Incorporated in 1981, Emcure Pharma manufactures off-patent generic medicines, injectables, and active pharmaceutical ingredients (APIs) across various therapeutic areas. The company operates 13 manufacturing facilities across India and supplies its products to 70 countries. India is its largest market and makes up for 48 per cent of its revenue, followed by Europe with a revenue share of 21 per cent and the US with a share of 14 per cent.

Strengths of Emcure Pharma

• Leadership position: Emcure has a strong presence in the domestic market. It is the market leader in the gynaecology and HIV antiviral therapeutics, and is among the top 10 players in five other therapeutic areas in terms of market share.
  
• Vertical integration: The company enjoys operational efficiency, thanks to its vertical integration. It manufactures APIs on its own, which are used in production of finished dosages. For distribution, it has established a strong network in the international markets by either developing its own front-end distribution capabilities, or by joining hands with local players and leveraging their distribution network.

Weaknesses of Emcure Pharma

• Intense competition: Emcure manufactures off-patent products that don't have any significant barriers for entering the market. Hence, the company faces severe competition, exposing it to high price erosion. This also impacted its profitability in FY23 and FY24.
  
• Strict regulatory requirements: Pharma companies operate in a very strict regulatory environment both in domestic and international markets. The companies are required to follow a long and tedious regulatory process before starting operations or launching new products. Any negative or unfavourable observation from a regulatory body can lead to significant delays in the company's operations.

Risk report

Company and business

• Are Emcure Pharma's earnings before tax more than Rs 50 crore in the last 12 months?
  Yes. The company reported a profit before tax of Rs 727 crore as of FY24.
  
• Will Emcure Pharma be able to scale up its business?
  Yes. A strong market presence with leadership in niche categories and favourable macroeconomic conditions will help the company scale its business.
  
• Does Emcure Pharma have a recognisable brand recall with client stickiness?
  Yes. It is among the top 10 domestic players (in terms of market share) in multiple chronic therapeutic areas. It also boasts the largest market share in the gynaecology and HIV antivirals in the Indian market.
  
• Does the company have a credible moat?
  No. The company manufactures easy to replicate off-patent medicines and it has to compete with multiple big and small companies in the market.

Management

• Do any of the company's founders still hold at least a 5 per cent stake? Or do promoters have over 25 per cent stake in the company?
  Yes. Post the IPO, the promoters will hold a stake of 78 per cent.
  
• Do the top three managers have over 15 years of combined leadership at Emcure Pharma?
  Yes. The company's MD and CEO has been associated with the company since its incorporation in 1981.
  
• Is the management trustworthy? Is it transparent in its disclosures, which are consistent with SEBI guidelines?
  Yes. No information suggests otherwise.
  
• Is the company's accounting policy stable?
  Yes. No information suggests otherwise.
  
• Is Emcure Pharma free of promoter pledging of shares?
  Yes. The company's promoters have not pledged any shares.

Financials

• Did the company generate a current and three-year average ROE of more than 15 per cent and a ROCE of more than 18 per cent?
  Yes. Emcure Pharma's three-year average ROE and ROCE were 23.8 and 23.7 per cent, respectively. The ROE and ROCE for FY24 were nearly 17 and 19 per cent, respectively.
  
• Was the company operating cash flow positive during the last three years?
  Yes. The company's operating cash flows were positive between FY22 and FY24.
  
• Is the company's net debt-to-equity ratio less than one?
  Yes. Emcure Pharma had a net debt-to-equity ratio of 0.6 as of March 2024.
  
• Is Emcure Pharma free from reliance on huge working capital for day-to-day affairs?
  No. High working capital requirement is an industry-wide feature and Emcure is no exception. It recorded a cash conversion cycle of 114 days in FY24.
  
• Can the company run its business without relying on external funding in the next three years?
  Yes. Although it carries significant debt on its balance sheet, the fresh proceeds from the IPO coupled with its ability to consistently generate operating cash flows will allow the company to not require external funding in the near future.
  
• Is Emcure Pharma free from meaningful contingent liabilities?
  Yes. The company was free from meaningful contingent liabilities as of March 2024.

Valuations

• Does the stock offer an operating earnings yield of more than 8 per cent on its enterprise value?
  No. The stock offers an operating earnings yield of 4.3 per cent on its enterprise value.
  
• Is the stock's price-to-earnings less than its peers' median level?
  Yes. The stock will trade at a P/E ratio of 36.1 times compared to its peers' median P/E of 39 times.
  
• Is the stock's price-to-book value less than its peers' average level?
  Yes. The stock is valued at a P/B ratio of 5.1 times compared to its peers' median P/B of 8.6 times.

Disclaimer: This is not a stock recommendation. Do your due diligence before investing.

Also read: Another IPO frenzy begins